Inventor · disambiguated record
Mark E. Layton
Also filed as: LAYTON MARK · LAYTON MARK E · LAYTON MARK ERIC
29 granted patents·18 pending applications·112 citations·filing 2004–2024
95Inventor score
Files withMERCK SHARP & DOHME12MERCK SHARP & DOHME LLC11LAYTON MARK E7KELLY III MICHAEL J3MERCK & CO INC3
Top patents by PatentIndex Score
47 records- 0194US7576209B2Inhibitors of Akt activityMERCK & CO INC·Filed 2007·Granted Aug 18, 2009·29 cites·1 claims
- 0293US7589068B2Inhibitors of Akt activityMERCK & CO INC·Filed 2006·Granted Sep 15, 2009·16 cites·5 claims
- 0391US11377438B22-amino-n-heteroaryl-nicotinamides as Nav1.8 inhibitorsMERCK SHARP & DOHME·Filed 2019·Granted Jul 5, 2022·6 cites·22 claims
- 0490US8765784B2Positive allosteric modulators of MGLUR2ARRINGTON KENNETH L·Filed 2011·Granted Jul 1, 2014·20 cites·19 claims
- 0583US8207169B2Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula DFURUYAMA HIDETOMO·Filed 2009·Granted Jun 26, 2012·9 cites·5 claims
- 0683US8008317B2Inhibitors of akt activtiyMERCK SHARP & DOHME·Filed 2006·Granted Aug 30, 2011·9 cites·4 claims
- 0780US2025084064A12-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitorsMERCK SHARP & DOHME LLC·Filed 2024·Application pending·0 cites
- 0877US8952005B2Substituted 1,3-benzothiazol-2(3H)-ones and [1,3]thiazolo[5,4-B]pyridin-2(1H)-ones as positive allosteric modulators of mGluR2MERCK SHARP & DOHME·Filed 2013·Granted Feb 10, 2015·3 cites·14 claims
- 0977US8168652B2Inhibitors of AKT activitySANDERSON PHILIP E·Filed 2010·Granted May 1, 2012·7 cites·8 claims
- 1077US7910561B2Inhibitors of Akt activityMERCK SHARP & DOHME·Filed 2005·Granted Mar 22, 2011·3 cites·4 claims
- 1175US9062059B2Pyrimidine PDE10 inhibitorsCOX CHRISTOPHER D·Filed 2012·Granted Jun 23, 2015·3 cites·37 claims
- 1272US12195445B22-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitorsMERCK SHARP & DOHME LLC·Filed 2022·Granted Jan 14, 2025·0 cites·15 claims
- 1372US10519147B2Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channelsMERCK SHARP & DOHME·Filed 2016·Granted Dec 31, 2019·1 cites·18 claims
- 1470US9624208B2Benzoxazolinone compounds with selective activity in voltage-gated sodium channelsMERCK SHARP & DOHME·Filed 2013·Granted Apr 18, 2017·1 cites·5 claims
- 1570US9586968B2Bicycloamine-substituted-N-benzenesulfonamide compounds with selective activity in voltage-gated sodium channelsMERCK SHARP & DOHME·Filed 2014·Granted Mar 7, 2017·2 cites·19 claims
- 1670US2023312528A12-oxo-imidazolidine-4-carboxamides as nav1.8 inhibitorsMERCK SHARP & DOHME LLC·Filed 2023·Application pending·0 cites
- 1766US8993779B2Positive allosteric modulators of MGLUR2DUDKIN VADIM Y·Filed 2011·Granted Mar 31, 2015·1 cites·9 claims
- 1864US9388179B2N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channelsMERCK SHARP & DOHME·Filed 2013·Granted Jul 12, 2016·1 cites·20 claims
- 1964US2024228535A1Protease inhibitors for treating or preventing coronavirus infectionMERCK SHARP & DOHME LLC·Filed 2023·Application pending·0 cites
- 2063US2024287124A1Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitorsMERCK SHARP & DOHME LLC·Filed 2024·Application pending·0 cites
- 2162US11802122B22-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitorsMERCK SHARP & DOHME·Filed 2021·Granted Oct 31, 2023·0 cites·46 claims
- 2262US9273040B2Benzoxazolinone compounds with selective activity in voltage-gated sodium channelsLAYTON MARK E·Filed 2012·Granted Mar 1, 2016·1 cites·22 claims
- 2359US2025223259A1Protease inhibitors for treating or preventing coronavirus infectionMERCK SHARP & DOHME LLC·Filed 2023·Application pending·0 cites
- 2458US8536193B2Inhibitors of AKT activityFURUYAMA HIDETOMO·Filed 2009·Granted Sep 17, 2013·0 cites·2 claims
- 2557US2009253734A1Inhibitors of akt activityKELLY III MICHAEL J·Filed 2009·Application pending·0 cites
- 2656US2022380338A1Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitorsMERCK SHARP & DOHME LLC·Filed 2022·Application pending·0 cites
- 2756US2024246932A1Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitorsMERCK SHARP & DOHME LLC·Filed 2022·Application pending·0 cites
- 2853US12246008B24-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channelsMERCK SHARP & DOHME LLC·Filed 2019·Granted Mar 11, 2025·0 cites·17 claims
- 2953US2010292241A13,5-substituted-1,3-oxazolidin-2-one derivativesMERCK SHARP & DOHME·Filed 2009·Application pending·0 cites
- 3052US7452893B24-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonistsMERCK & CO INC·Filed 2004·Granted Nov 18, 2008·0 cites·9 claims
- 3150US2005054658A14-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonistsFiled 2004·Application pending·0 cites
- 3249US12427159B2Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channelsMERCK SHARP & DOHME LLC·Filed 2020·Granted Sep 30, 2025·0 cites·15 claims
- 3349US2023227405A15-oxopyrrolidine-3-carboxamides as nav1.8 inhibitorsARASAPPAN ASHOK·Filed 2021·Application pending·0 cites
- 3447US8288407B2Substituted naphthyridine compounds as inhibitors of Akt activityKELLY III MICHAEL J·Filed 2011·Granted Oct 16, 2012·0 cites·4 claims
- 3547US2010022573A1Inhibitors of akt activityLAYTON MARK E·Filed 2007·Application pending·0 cites
- 3646US10968210B2Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channelsMERCK SHARP & DOHME·Filed 2017·Granted Apr 6, 2021·0 cites·19 claims
- 3744US12344595B22-amino-n-phenyl-nicotinamides as NAV1.8 inhibitorsMERCK SHARP & DOHME LLC·Filed 2019·Granted Jul 1, 2025·0 cites·15 claims
- 3843US2009124600A1N-Alkyl-Azacycloalkyl NMDA/NR2B AntagonistsLAYTON MARK E·Filed 2006·Application pending·0 cites
- 3942US2013035332A1Substituted 1,3-Benzothiazol-2(3H)-Ones and [1,3]Thiazolo[5,4-B]Pyridin-2(IH)-Ones as Positive Allosteric Modulators of MGLUR2LAYTON MARK E·Filed 2011·Application pending·0 cites
- 4040US10442778B2N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channelsMERCK SHARP & DOHME·Filed 2017·Granted Oct 15, 2019·0 cites·18 claims
- 4138US8481503B2Combination cancer therapy with an AKT inhibitor and other anticancer agentsLAYTON MARK E·Filed 2010·Granted Jul 9, 2013·0 cites·5 claims
- 4238US2007293515A11,3-Disubstituted Heteroaryl Nmda/Nr2b AntagonistsLAYTON MARK E·Filed 2005·Application pending·0 cites
- 4335US9315518B2Imidazopyridin-2-one derivativesFIJI HANNAH D·Filed 2012·Granted Apr 19, 2016·0 cites·9 claims
- 4435US2013203756A1Isoindoline pde10 inhibitorsBUNDA JAMIE L·Filed 2011·Application pending·0 cites
- 4534US9108937B2Positive allosteric modulators of mGluR2LAYTON MARK E·Filed 2011·Granted Aug 18, 2015·0 cites·26 claims
- 4632US2011288090A1Inhibitors of AKT ActivityARMSTRONG DONNA J·Filed 2010·Application pending·0 cites
- 4731US2012252806A1Inhibitors of akt activityKELLY III MICHAEL J·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark E. Layton files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →